Radiopharm Theranostics Limited (RADX) Earnings History
Annual and quarterly earnings data from 2021 to 2024
Loading earnings history...
RADX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RADX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 1.1% | -1050.6% | -1055.3% |
| 2023 | 100.0% | -12238.4% | -16024.3% |
| 2022 | 100.0% | -11803.3% | -11838.6% |
| 2021 | 100.0% | -225527.7% | -343550.9% |
Download Data
Export RADX earnings history in CSV or JSON format
Free sign-in required to download data
Radiopharm Theranostics Limited (RADX) Earnings Overview
As of May 8, 2026, Radiopharm Theranostics Limited (RADX) reported trailing twelve-month net income of -$38M, reflecting +85.3% year-over-year growth. The company earned $-5.28 per diluted share over the past four quarters, with a net profit margin of -1055.3%.
Looking at the long-term picture, RADX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$30M in fiscal 2021.
Radiopharm Theranostics Limited is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RNW ($11.97B net income, 3.9% margin), RNAZ (-$27M net income), LNTH ($279M net income, 15.2% margin), RADX has room to improve margins relative to the peer group. Compare RADX vs RNW →
RADX Earnings vs Peers
Earnings metrics vs comparable public companies
RADX Historical Earnings Data (2021–2024)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$38M | +20.0% | -$38M | $-5.28 | -1055.3% | -1050.6% |
| 2023 | -$48M | -38.5% | -$37M | $-36.00 | -16024.3% | -12238.4% |
| 2022 | -$35M | -14.1% | -$35M | $-33.00 | -11838.6% | -11803.3% |
| 2021 | -$30M | - | -$20M | $-29.76 | -343550.9% | -225527.7% |
See RADX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RADX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RADX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRADX — Frequently Asked Questions
Quick answers to the most common questions about buying RADX stock.
Is RADX growing earnings?
RADX EPS is $-5.28, with earnings growth accelerating to +85.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-38M.
What are RADX's profit margins?
Radiopharm Theranostics Limited net margin is -1055.3%, with operating margin at -1050.6%. Below-average margins reflect competitive or cost pressures.
How consistent are RADX's earnings?
RADX earnings data spans 2021-2024. The accelerating earnings trend is +85.3% YoY. Historical data enables comparison across business cycles.